Amgen Inc. (AMGN)

$264.07

-1.57

(-0.59%)▲

Market is closed - opens 7 PM, 18 Apr 2024
star icon

Amgen, Inc. is a biopharmaceutical company that is involved in the development and commercialization of drugs for various diseases.

Insights on Amgen Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 6.90B → 8.19B (in $), with an average increase of 15.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.73B → 767.0M (in $), with an average decrease of 55.7% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 103.0% return, outperforming this stock by 95.7%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 296.7% return, outperforming this stock by 293.4%

Performance

  • $263.42
    $268.58
    $264.07
    downward going graph

    0.25%

    Downside

    Day's Volatility :1.92%

    Upside

    1.68%

    downward going graph
  • $203.55
    $324.63
    $264.07
    downward going graph

    22.92%

    Downside

    52 Weeks Volatility :37.3%

    Upside

    18.66%

    downward going graph

Returns

PeriodAmgen Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-13.27%
-0.7%
4.2%
6 Months
-6.88%
6.6%
17.8%
1 Year
7.31%
3.7%
29.0%
3 Years
3.16%
14.0%
11.6%

Highlights

Market Capitalization
142.4B
Book Value
$11.64
Dividend Share
8.52
Dividend Yield
3.39%
Earnings Per Share (EPS)
12.49
PE Ratio
21.27
PEG Ratio
2.39
Wall Street Target Price
307.5
Profit Margin
23.83%
Operating Margin TTM
8.15%
Return On Assets TTM
6.29%
Return On Equity TTM
135.79%
Revenue TTM
28.2B
Revenue Per Share TTM
52.69
Quarterly Revenue Growth YOY
19.8%
Gross Profit TTM
19.9B
EBITDA
12.2B
Diluted Eps TTM
12.49
Quarterly Earnings Growth YOY
-0.52
EPS Estimate Current Year
19.55
EPS Estimate Next Year
21.11
EPS Estimate Current Quarter
4.6
EPS Estimate Next Quarter
4.41

Analyst Recommendation

Buy
    51%Buy
    40%Hold
    8%Sell
Based on 35 Wall street analysts offering stock ratings for Amgen Inc.(by analysts ranked 0 to 5 stars)
Based on 35 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
17
15
Hold
14
12
14
Sell
3
3
4

Analyst Forecast

What analysts predicted

Upside of 16.45%

Current $264.07
Target $307.50

Company Financials

FY18Y/Y Change
Revenue
23.7B
↑ 3.93%
Net Income
8.4B
↑ 324.15%
Net Profit Margin
35.35%
↑ 26.69%
FY19Y/Y Change
Revenue
23.4B
↓ 1.62%
Net Income
7.8B
↓ 6.58%
Net Profit Margin
33.57%
↓ 1.78%
FY20Y/Y Change
Revenue
25.4B
↑ 8.83%
Net Income
7.3B
↓ 7.37%
Net Profit Margin
28.57%
↓ 5.0%
FY21Y/Y Change
Revenue
26.0B
↑ 2.18%
Net Income
5.9B
↓ 18.87%
Net Profit Margin
22.68%
↓ 5.89%
FY22Y/Y Change
Revenue
26.3B
↑ 1.32%
Net Income
6.6B
↑ 11.18%
Net Profit Margin
24.89%
↑ 2.21%
FY23Y/Y Change
Revenue
28.2B
↑ 7.09%
Net Income
6.7B
↑ 2.52%
Net Profit Margin
23.83%
↓ 1.06%
Q3 FY22Q/Q Change
Revenue
6.7B
↑ 0.88%
Net Income
2.1B
↑ 62.72%
Net Profit Margin
32.22%
↑ 12.25%
Q4 FY22Q/Q Change
Revenue
6.8B
↑ 2.81%
Net Income
1.6B
↓ 24.59%
Net Profit Margin
23.63%
↓ 8.59%
Q1 FY23Q/Q Change
Revenue
6.1B
↓ 10.73%
Net Income
2.8B
↑ 75.8%
Net Profit Margin
46.54%
↑ 22.91%
Q2 FY23Q/Q Change
Revenue
7.0B
↑ 14.43%
Net Income
1.4B
↓ 51.46%
Net Profit Margin
19.74%
↓ 26.8%
Q3 FY23Q/Q Change
Revenue
6.9B
↓ 1.19%
Net Income
1.7B
↑ 25.45%
Net Profit Margin
25.06%
↑ 5.32%
Q4 FY23Q/Q Change
Revenue
8.2B
↑ 18.73%
Net Income
767.0M
↓ 55.66%
Net Profit Margin
9.36%
↓ 15.7%
FY18Y/Y Change
Total Assets
66.4B
↓ 16.93%
Total Liabilities
53.9B
↓ 1.46%
FY19Y/Y Change
Total Assets
59.7B
↓ 10.1%
Total Liabilities
50.0B
↓ 7.2%
FY20Y/Y Change
Total Assets
62.9B
↑ 5.43%
Total Liabilities
53.5B
↑ 7.01%
FY21Y/Y Change
Total Assets
61.2B
↓ 2.83%
Total Liabilities
54.5B
↑ 1.73%
FY22Y/Y Change
Total Assets
65.1B
↑ 6.47%
Total Liabilities
61.5B
↑ 12.84%
FY23Y/Y Change
Total Assets
97.2B
↑ 49.19%
Total Liabilities
90.9B
↑ 47.94%
Q3 FY22Q/Q Change
Total Assets
63.7B
↑ 7.43%
Total Liabilities
60.0B
↑ 5.58%
Q4 FY22Q/Q Change
Total Assets
65.1B
↑ 2.23%
Total Liabilities
61.5B
↑ 2.35%
Q1 FY23Q/Q Change
Total Assets
88.7B
↑ 36.24%
Total Liabilities
83.4B
↑ 35.65%
Q2 FY23Q/Q Change
Total Assets
90.3B
↑ 1.75%
Total Liabilities
83.5B
↑ 0.14%
Q3 FY23Q/Q Change
Total Assets
90.5B
↑ 0.29%
Total Liabilities
82.9B
↓ 0.73%
Q4 FY23Q/Q Change
Total Assets
97.2B
↑ 7.31%
Total Liabilities
90.9B
↑ 9.71%
FY18Y/Y Change
Operating Cash Flow
11.3B
↑ 1.06%
Investing Cash Flow
14.3B
↓ 456.34%
Financing Cash Flow
-22.5B
↑ 241.07%
FY19Y/Y Change
Operating Cash Flow
9.2B
↓ 19.0%
Investing Cash Flow
5.7B
↓ 60.19%
Financing Cash Flow
-15.8B
↓ 29.89%
FY20Y/Y Change
Operating Cash Flow
10.5B
↑ 14.72%
Investing Cash Flow
-5.4B
↓ 194.61%
Financing Cash Flow
-4.9B
↓ 69.13%
FY21Y/Y Change
Operating Cash Flow
9.3B
↓ 11.77%
Investing Cash Flow
733.0M
↓ 113.57%
Financing Cash Flow
-8.3B
↑ 69.94%
FY22Y/Y Change
Operating Cash Flow
9.7B
↑ 4.97%
Investing Cash Flow
-6.0B
↓ 924.56%
Financing Cash Flow
-4.0B
↓ 51.19%
Q3 FY22Q/Q Change
Operating Cash Flow
3.0B
↑ 54.3%
Investing Cash Flow
-267.0M
↓ 87.82%
Financing Cash Flow
1.6B
↓ 249.53%
Q4 FY22Q/Q Change
Operating Cash Flow
2.6B
↓ 11.05%
Investing Cash Flow
-3.5B
↑ 1200.75%
Financing Cash Flow
-1.0B
↓ 166.06%
Q1 FY23Q/Q Change
Operating Cash Flow
1.1B
↓ 59.83%
Investing Cash Flow
1.4B
↓ 139.1%
Financing Cash Flow
21.5B
↓ 2150.43%
Q2 FY23Q/Q Change
Operating Cash Flow
4.1B
↑ 286.18%
Investing Cash Flow
-211.0M
↓ 115.54%
Financing Cash Flow
-1.2B
↓ 105.63%

Technicals Summary

Sell

Neutral

Buy

Amgen Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Amgen Inc.
Amgen Inc.
-2.52%
-6.88%
7.31%
3.16%
48.8%
Eli Lilly And Company
Eli Lilly And Company
-1.56%
23.64%
102.96%
295.89%
551.71%
Johnson & Johnson
Johnson & Johnson
-7.65%
-5.21%
-10.09%
-11.01%
5.27%
Merck & Co. Inc.
Merck & Co. Inc.
3.24%
22.92%
9.18%
61.43%
71.29%
Abbvie Inc
Abbvie Inc
-7.98%
10.03%
2.92%
51.23%
111.74%
Pfizer Inc.
Pfizer Inc.
-8.3%
-19.07%
-37.31%
-34.7%
-35.45%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Amgen Inc.
Amgen Inc.
21.27
21.27
2.39
19.55
1.36
0.06
0.03
11.64
Eli Lilly And Company
Eli Lilly And Company
128.31
128.31
1.43
12.51
0.48
0.12
0.01
11.98
Johnson & Johnson
Johnson & Johnson
27.78
27.78
0.89
10.65
0.18
0.08
0.03
28.57
Merck & Co. Inc.
Merck & Co. Inc.
893.29
893.29
0.1
8.56
0.01
0.03
0.02
14.85
Abbvie Inc
Abbvie Inc
59.98
59.98
0.45
11.11
0.35
0.08
0.04
5.87
Pfizer Inc.
Pfizer Inc.
69.43
69.43
0.26
2.21
0.02
0.02
0.07
15.77
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Amgen Inc.
Amgen Inc.
Buy
$142.4B
48.8%
21.27
23.83%
Eli Lilly And Company
Eli Lilly And Company
Buy
$713.8B
551.71%
128.31
15.36%
Johnson & Johnson
Johnson & Johnson
Hold
$348.1B
5.27%
27.78
41.28%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$316.8B
71.29%
893.29
0.61%
Abbvie Inc
Abbvie Inc
Buy
$287.8B
111.74%
59.98
8.95%
Pfizer Inc.
Pfizer Inc.
Buy
$145.5B
-35.45%
69.43
3.62%

Institutional Holdings

  • Vanguard Group Inc

    9.15%

  • BlackRock Inc

    8.92%

  • State Street Corporation

    5.50%

  • PRIMECAP Management Company

    2.72%

  • Morgan Stanley - Brokerage Accounts

    2.69%

  • Geode Capital Management, LLC

    2.30%

Corporate Announcements

  • Amgen Inc. Dividends March,2024

    In the quarter ending March,2024. Amgen Inc. has declared dividend of $2.25

    Read More

Company Information

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

Organization
Amgen Inc.
Employees
26700
CEO
Mr. Robert A. Bradway
Industry
Health Technology

Discover More

FAQs